J Cancer 2021; 12(10):2952-2959. doi:10.7150/jca.53356 This issue Cite

Research Paper

Pygo2 as a novel biomarker in gastric cancer for monitoring drug resistance by upregulating MDR1

Dongdong Zhang1, Yu Liu2, Qiuwan Wu2, Yahong Zheng3, Natasha Mupeta Kaweme4, Zhiming Zhang2, Mingquan Cai2✉, Youhong Dong1✉

1. Department of Oncology, Xiangyang No. 1 People's Hospital, Hubei University of Medicine, Xiangyang, Hubei 441000, China.
2. Department of Medical Oncology, Xiamen Key Laboratory of Antitumor Drug Transformation Research, The First Affiliated Hospital of Xiamen University, School of clinical Medicine, Fujian Medical University, Xiamen 361003, Fujian Province, P.R. China.
3. Xiamen Huli District Maternal and Child Health Hospital, 361005 Xiamen, Fujian, China.
4. Department of Hematology, Zhongnan Hospital, Wuhan University, Wuhan, P.R. China.

Citation:
Zhang D, Liu Y, Wu Q, Zheng Y, Kaweme NM, Zhang Z, Cai M, Dong Y. Pygo2 as a novel biomarker in gastric cancer for monitoring drug resistance by upregulating MDR1. J Cancer 2021; 12(10):2952-2959. doi:10.7150/jca.53356. https://www.jcancer.org/v12p2952.htm
Other styles

File import instruction

Abstract

Graphic abstract

Chemotherapy is the main therapy for gastric cancer (GC) both before and after surgery, but the emergence of multidrug resistance (MDR) often leads to disease progression and recurrence. P-glycoprotein, encoded by MDR1, is a well-known multidrug efflux transporter involved in drug resistance development. Pygo2 overexpression has been identified in several cancers. Previous studies have shown that abnormal expression of Pygo2 is related to tumorigenesis, chemoresistance, and tumor progression. In this study, to evaluate the underlying relationship between Pygo2 and MDR1 in GC, we constructed GC drug-resistant cell lines, SGC7901/cis-platinum (DDP), and collected tissue from GC patients' pre-and post-chemotherapy. We found that Pygo2 was overexpressed in GC, especially in GC drug-resistant cell lines and GC patients who underwent neoadjuvant DDP-based chemotherapy. Pygo2 overexpression may precede MDR1 and correlates with MDR1 in GC patients. Furthermore, knock-down of Pygo2 induced downregulation of MDR1 and restored SGC7901/DDP's sensitivity to DDP. Further mechanistic analysis demonstrated that Pygo2 could modulate MDR1 transcription by binding to the MDR1 promoter region and promoting MDR1 activation. The overall findings reveal that Pygo2 may be a promising biomarker for monitoring drug resistance in GC by regulating MDR1.

Keywords: Pygo2, gastric cancer, biomarker, drug resistance, MDR1


Citation styles

APA
Zhang, D., Liu, Y., Wu, Q., Zheng, Y., Kaweme, N.M., Zhang, Z., Cai, M., Dong, Y. (2021). Pygo2 as a novel biomarker in gastric cancer for monitoring drug resistance by upregulating MDR1. Journal of Cancer, 12(10), 2952-2959. https://doi.org/10.7150/jca.53356.

ACS
Zhang, D.; Liu, Y.; Wu, Q.; Zheng, Y.; Kaweme, N.M.; Zhang, Z.; Cai, M.; Dong, Y. Pygo2 as a novel biomarker in gastric cancer for monitoring drug resistance by upregulating MDR1. J. Cancer 2021, 12 (10), 2952-2959. DOI: 10.7150/jca.53356.

NLM
Zhang D, Liu Y, Wu Q, Zheng Y, Kaweme NM, Zhang Z, Cai M, Dong Y. Pygo2 as a novel biomarker in gastric cancer for monitoring drug resistance by upregulating MDR1. J Cancer 2021; 12(10):2952-2959. doi:10.7150/jca.53356. https://www.jcancer.org/v12p2952.htm

CSE
Zhang D, Liu Y, Wu Q, Zheng Y, Kaweme NM, Zhang Z, Cai M, Dong Y. 2021. Pygo2 as a novel biomarker in gastric cancer for monitoring drug resistance by upregulating MDR1. J Cancer. 12(10):2952-2959.

This is an open access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/). See http://ivyspring.com/terms for full terms and conditions.
Popup Image